Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage

Buyeverov, A. O.; Олегович, Буеверов Алексей; Богомолов, П. О.; Олегович, Богомолов Павел; Mayev, I.V.; Вениаминович, Маев Игорь; Мациевич, М. В.; Владиславовна, Мациевич Мария; Uvarova, Olga V.; Владимировна, Уварова Ольга

doi:10.26442/00403660.2019.02.000125

Cited by 7 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Значительное снижение концентрации иона аммония (от 135,5 мкмоль/л до 82,9 мкмоль/л, p=0.002) наблюдалось через 5 месяцев терапии. Критическая частота КЧСМ достоверно повышалась уже после 1-го месяца терапии (p=0.008) [18].…”

Section: орнитин и цирроз печениunclassified

Systematic computer analysis of ornithine research to identify the most promising trends in therapeutic use - focus on liver function

Громова

Торшин

Лазебник

et al. 2021

jour

View full text Add to dashboard Cite

This analysis of 21,626 publications on fundamental and clinical studies of ornithine showed that the pharmacological effects of ornithine are due to its participation in the neutralization of ammonia in the urea cycle, amino acid metabolism, intracellular protein synthesis, inflammation and the functioning of T-cell immunity. The use of ornithine is promising for hyperammonemia, steatohepatosis and other liver pathologies, hepatic encephalopathy and sarcopenia. Ornithine maintains hormonal balance by promoting the production of insulin and growth hormone.

show abstract

Section: орнитин и цирроз печениunclassified

Systematic computer analysis of ornithine research to identify the most promising trends in therapeutic use - focus on liver function

Громова

Торшин

Лазебник

et al. 2021

jour

View full text Add to dashboard Cite

show abstract

“… 8 Patients with hepatitis C at the pre-cirrhotic stage were shown to have significantly decreased blood concentrations of NH 4 + and improvement in psychometric testing after a trial of L-ornithine-L-aspartate (LOLA). 55 Additionally, LOLA has been shown to restore muscle protein synthesis in sarcopenic patients, thus enhancing skeletal muscle’s natural ability to metabolize NH 3 from the blood. 56 Conversely, reducing the production of NH 3 by preventing the degradation of Gln and glycine—2 amino acids responsible for much of its physiologic production—has been suggested.…”

Section: Treatmentmentioning

confidence: 99%

Hyperammonemia Post Lung Transplantation: A Review

Leger

Silverman

Hauck

et al. 2020

Clin Med Insights Circ Respir Pulm Med

View full text Add to dashboard Cite

Hyperammonemia is the pathological accumulation of ammonia in the blood, which can occur in many different clinical settings. Most commonly in adults, hyperammonemia occurs secondary to hepatic dysfunction; however, it is also known to be associated with other pathologies, surgeries, and medications. Although less common, hyperammonemia has been described as a rare, but consistent complication of solid organ transplantation. Lung transplantation is increasingly recognized as a unique risk factor for the development of this condition, which can pose grave health risks—including long-term neurological sequelae and even death. Recent clinical findings have suggested that patients receiving lung transplantations may experience postoperative hyperammonemia at rates as high as 4.1%. A wide array of etiologies has been attributed to this condition. A growing number of case studies and investigations suggest disseminated opportunistic infection with Ureaplasma or Mycoplasma species may drive this metabolic disturbance in lung transplant recipients. Regardless of the etiology, hyperammonemia presents a severe clinical problem with reported mortality rates as high as 75%. Typical treatment regimens are multimodal and focus on 3 main avenues of management: (1) the reduction of impact on the brain through the use of neuroprotective medications and decreasing cerebral edema, (2) augmentation of mechanisms for the elimination of ammonia from the blood via hemodialysis, and (3) the diminishment of processes producing predominantly using antibiotics. The aim of this review is to detail the pathophysiology of hyperammonemia in the setting of orthotopic lung transplantation and discuss methods of identifying and managing patients with this condition.

show abstract

“…LOLA may be administered orally or parenterally. The benefits of LOLA for the treatment of HE have been known for 50 years (Buyeverov et al 2019 ; Kircheis and Luth 2019 ). However, in the treatment of MHE, there are no unified conclusions about the efficacy of LOLA.…”

Section: Treatment Of Mhe: Cognition Recoverymentioning

confidence: 99%

“…After 5 months treatment, the NCT parameters reached their minimum values and remained at that level throughout the study. (Buyeverov et al 2019). Alvaresda-Silva et al showed that LOLA was useful in preventing further episodes of HE, but was no better in treating MHE (Alvares-da-Silva et al 2014).…”

Section: Lolamentioning

confidence: 99%

Cognition-tracking-based strategies for diagnosis and treatment of minimal hepatic encephalopathy

et al. 2020

View full text Add to dashboard Cite

Minimal hepatic encephalopathy (MHE), which shows mild cognitive impairment, is a subtle complication of cirrhosis that has been shown to affect daily functioning and quality of life. However, until 2014, relevant guidelines do not give much attention to the diagnosis and treatment of MHE, resulting in patients being ignored and denied the benefits of treatment. In this review, we summarize recent cognition-based research about (1) alteration of nerve cells, including astrocytes, microglial cells and neurons, in mild cognitive impairment in MHE; (2) comparison of methods in detecting cognitive impairment in MHE; and (3) comparison of methods for therapy of cognitive impairment in MHE. We hope to provide information about diagnosis and treatment of cognitive impairment in patients with MHE.

show abstract

Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage

Cited by 7 publications

References 0 publications

Systematic computer analysis of ornithine research to identify the most promising trends in therapeutic use - focus on liver function

Systematic computer analysis of ornithine research to identify the most promising trends in therapeutic use - focus on liver function

Hyperammonemia Post Lung Transplantation: A Review

Cognition-tracking-based strategies for diagnosis and treatment of minimal hepatic encephalopathy

Contact Info

Product

Resources

About